RT Journal Article
T1 Expert-Agreed Practical Recommendations on the Use of Cladribine.
A1 Meca-Lallana, Virginia
A1 García Domínguez, José M
A1 López Ruiz, Rocío
A1 Martín-Martínez, Jesús
A1 Arés Luque, Adrián
A1 Hernández Pérez, Miguel A
A1 Prieto González, José M
A1 Landete Pascual, Lamberto
A1 Sastre-Garriga, Jaume
K1 Cladribine
K1 Consensus
K1 Disease-modifying drugs
K1 Expert opinion
K1 Relapsing multiple sclerosis
K1 Treatment response
AB Cladribine is a disease-modifying selective immune reconstitution oral therapy for adult patients with highly active relapsing multiple sclerosis (RMS). It was approved in the USA in 2019 and in Europe in 2017, thus there are still gaps in existing guidelines for using cladribine tablets in clinical practice. Nine experts with extensive experience in managing patients with multiple sclerosis in Spain identified some of the unanswered questions related to the real-life use of cladribine tablets. They reviewed the available clinical trial data and real-world evidence, including their own experiences of using cladribine, over the course of three virtual meetings held between November 2020 and January 2021. This article gathers their practical recommendations to aid treatment decision-making and optimise the use of cladribine tablets in patients with RMS. The consensus recommendations cover the following areas: candidate patient profiles, switching strategies (to and from cladribine), managing response to cladribine and safety considerations.
SN 2193-8253
YR 2022
FD 2022-09-06
LK http://hdl.handle.net/10668/21508
UL http://hdl.handle.net/10668/21508
LA en
DS RISalud
RD Apr 5, 2025